INAPRUBAHAN ng Philippine Board of Investments (BOI) ang application for registration ng Lloyd Laboratories, Inc. bilang domestic producer ng Molnupiravir, isang oral therapy para sa COVID-19 patients.
“Amid the steep surge of COVID-19 cases exacerbated by the emergence of new variants, it is a crucial and urgent step to produce oral therapies locally to reduce hospitalization, and for those who will be hospitalized—to lessen the period of hospitalization, and to prevent the death of Filipinos who contracted the virus. In fact, the BOI has been at the forefront of harnessing the Philippine manufacturing capacity in the fight against the pandemic including through the repurposing project for Personal Protective Equipment (PPEs), disinfectants, and ventilators; and industrial coordination to ensure that oxygen is available across all hospitals in the country during the Delta surge,” wika ni Trade Secretary at BOI Chairman Ramon Lopez.
Isang existing manufacturer ng iba’t ibang gamot, pinalawak ng Lloyd Laboratories ang production facility nito sa Malolos, Bulacan, na gagamitin sa pagprodyus ng gamot.
May tinatayang halaga na P24 million at annual capacity na one million 400 mg capsules ng Molnupiravir, ang proyekto ay inaasahang magsisimula ngayong Enero.
“The project was approved for complying with the qualification requirements for ‘All Qualified Activities Relating to the Fight against the COVID-19 Pandemic – Essential Goods’ Listing of the 2020 IPP as the transitional Strategic Investment Priorities Plan (SIPP) under the Corporate Recovery and Tax Incentives for Enterprises Act (CREATE) Law,” ayon sa DTI.
Ang Lloyd Laboratories ay nakakuha ng direct technology transfer sa Molnupiravir production mula Optimus Pharma, isang integrated pharmaceutical organization sa Hyderabad. Sinabi ng laboratoryo na layon nitong makagawa ng produkto sa lalong madaling panahon.
Ang Suggested Retail Price (SRP) ng locally-made Molnupiravir ay P65/pill, na mas mababa sa imported counterpart nito na nasa P100 hanggang P150 per pill.